266 related articles for article (PubMed ID: 28974264)
1. PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma.
Bai Y; Niu D; Huang X; Jia L; Kang Q; Dou F; Ji X; Xue W; Liu Y; Li Z; Feng Q; Lin D; Kakudo K
Diagn Pathol; 2017 Oct; 12(1):72. PubMed ID: 28974264
[TBL] [Abstract][Full Text] [Related]
2. In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related.
Bai Y; Guo T; Huang X; Wu Q; Niu D; Ji X; Feng Q; Li Z; Kakudo K
Virchows Arch; 2018 May; 472(5):779-787. PubMed ID: 29651624
[TBL] [Abstract][Full Text] [Related]
3. Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
Shi RL; Qu N; Luo TX; Xiang J; Liao T; Sun GH; Wang Y; Wang YL; Huang CP; Ji QH
Thyroid; 2017 Apr; 27(4):537-545. PubMed ID: 27825291
[TBL] [Abstract][Full Text] [Related]
4. Papillary Thyroid Carcinoma Emerging from Hashimoto Thyroiditis Demonstrates Increased PD-L1 Expression, Which Persists with Metastasis.
Lubin D; Baraban E; Lisby A; Jalali-Farahani S; Zhang P; Livolsi V
Endocr Pathol; 2018 Dec; 29(4):317-323. PubMed ID: 30121940
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive screening for PD-L1 expression in thyroid cancer.
Ahn S; Kim TH; Kim SW; Ki CS; Jang HW; Kim JS; Kim JH; Choe JH; Shin JH; Hahn SY; Oh YL; Chung JH
Endocr Relat Cancer; 2017 Feb; 24(2):97-106. PubMed ID: 28093480
[TBL] [Abstract][Full Text] [Related]
6. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status.
Paskaš S; Janković J; Marečko I; Išić Denčić T; Tatić S; Cvejić D; Savin S
Otolaryngol Head Neck Surg; 2014 Feb; 150(2):201-9. PubMed ID: 24255086
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
8. Role of cytotoxic T cells and PD-1 immune checkpoint pathway in papillary thyroid carcinoma.
Banerjee S; Nahar U; Dahiya D; Mukherjee S; Dey P; Gupta R; Radotra B; Sachdeva N; Sood A; Bhadada SK; Bhansali A
Front Endocrinol (Lausanne); 2022; 13():931647. PubMed ID: 36518249
[TBL] [Abstract][Full Text] [Related]
9. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
[TBL] [Abstract][Full Text] [Related]
10. Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.
Gandolfi G; Sancisi V; Torricelli F; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A
J Clin Endocrinol Metab; 2013 May; 98(5):E934-42. PubMed ID: 23533235
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
Wakasa T; Li Y; Bai Y; Liu Z; Ozaki T; Mori I; Miyauchi A; Kakudo K; Nakamura M
Pathol Res Pract; 2014 Nov; 210(11):733-8. PubMed ID: 25085839
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Significance of Categorizing Gastric Carcinoma by PD-L1 Expression and Tumor Infiltrating Lymphocytes.
Noh BJ; Kim JH; Eom DW
Ann Clin Lab Sci; 2018 Nov; 48(6):695-706. PubMed ID: 30610038
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 expression in rare and aggressive thyroid cancers: A preliminary investigation for a role of immunotherapy.
Boruah M; Gaddam P; Agarwal S; Mir RA; Gupta R; Sharma MC; S Deo SV; Nilima N
J Cancer Res Ther; 2023; 19(2):312-320. PubMed ID: 37006068
[TBL] [Abstract][Full Text] [Related]
14. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
15. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ
Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
[TBL] [Abstract][Full Text] [Related]
16. Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAF(V600E) Mutation and BRAF Pseudogene.
Lin JD; Fu SS; Chen JY; Lee CH; Chau WK; Cheng CW; Wang YH; Lin YF; Fang WF; Tang KT
Thyroid; 2016 May; 26(5):691-704. PubMed ID: 26914762
[TBL] [Abstract][Full Text] [Related]
17. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
[No Abstract] [Full Text] [Related]
18. BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration.
Angell TE; Lechner MG; Jang JK; Correa AJ; LoPresti JS; Epstein AL
Thyroid; 2014 Sep; 24(9):1385-93. PubMed ID: 24955518
[TBL] [Abstract][Full Text] [Related]
19. Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 Jan; 23(1):27-34. PubMed ID: 26598713
[TBL] [Abstract][Full Text] [Related]
20. Chronic Lymphocytic Thyroiditis with Oncocytic Metaplasia Influences PD-L1 Expression in Papillary Thyroid Carcinoma.
Santana VB; Krüger VM; Abrahão MCY; Cantú PLM; Brackmann RL; Pandolfi GM; Marisco LS; Remonatto G; Ferreira LA; Graudenz MS
Head Neck Pathol; 2024 Mar; 18(1):14. PubMed ID: 38457034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
